Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia.

Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia.
复制标题

DOI:
10.1021/acs.jmedchem.8b00241
复制
发表时间:
2018-05-10
影响因子:
7.3
通讯作者:
Chen Y
Chen Y
中科院分区:
医学1区
文献类型:
--
作者:
Li J;Li S;Guo J;Li Q;Long J;Ma C;Ding Y;Yan C;Li L;Wu Z;Zhu H;Li KK;Wen L;Zhang Q;Xue Q;Zhao C;Liu N;Ivanov I;Luo M;Xi R;Long H;Wang PG;Chen Y

文献摘要

参考文献

被引文献

相似文献

癌细胞的代谢重编程是肿瘤发生的必要条件,其中丙酮酸激酶的低活性异构体PKM2 (pyruvate kinase M2)起着关键作用。在这里,我们描述了一种天然产物衍生的micheliolide (MCL)的鉴定,它通过在PKM1中不包含的半胱氨酸424 (C424)残基上的共价结合选择性地激活PKM2。这种相互作用促进更多的四聚体形成,抑制赖氨酸433 (K433)乙酰化,并影响PKM2易位进入细胞核。此外,在斑马鱼异种移植模型中,具有与MCL相似特性的前体药物二甲氨基米heliolide (DMAMCL)显著抑制白血病细胞的生长和肿瘤发生。敲低PKM2表达的细胞实验证实MCL的作用依赖于PKM2的表达。DMAMCL目前正在澳大利亚进行临床试验。我们的发现可能为临床治疗提供有价值的药理机制,并有利于开发新的抗癌药物。
Metabolic reprogramming of cancer cells is essential for tumorigenesis in which pyruvate kinase M2 (PKM2), the low activity isoform of pyruvate kinase, plays a critical role. Herein, we describe the identification of a nature-product-derived micheliolide (MCL) that selectively activates PKM2 through the covalent binding at residue cysteine424 (C424), which is not contained in PKM1. This interaction promotes more tetramer formation, inhibits the lysine433 (K433) acetylation, and influences the translocation of PKM2 into the nucleus. In addition, the pro-drug dimethylaminomicheliolide (DMAMCL) with similar properties as MCL significantly suppresses the growth of leukemia cells and tumorigenesis in a zebrafish xenograft model. Cell-based assay with knock down PKM2 expression verifies that the effects of MCL are dependent on PKM2 expression. DMAMCL is currently in clinical trials in Australia. Our discovery may provide a valuable pharmacological mechanism for clinical treatment and benefit the development of new anticancer agents.
DOI: 10.1126/science.1211485
发表时间: 2011-12-02
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Anastasiou D;Poulogiannis G;Asara JM;Boxer MB;Jiang JK;Shen M;Bellinger G;Sasaki AT;Locasale JW;Auld DS;Thomas CJ;Vander Heiden MG;Cantley LC
通讯作者: Cantley LC
DOI: 10.1038/ncomms6566
发表时间: 2014-11-21
影响因子: 16.6
作者:
Jiang, Yuhui;Wang, Yugang;Wang, Ting;Hawke, David H.;Zheng, Yanhua;Li, Xinjian;Zhou, Qin;Majumder, Sadhan;Bi, Erfei;Liu, David X.;Huang, Suyun;Lu, Zhimin
通讯作者: Lu, Zhimin
DOI: 10.1208/pt0804105
发表时间: 2007-10-01
期刊: AAPS PHARMSCITECH
影响因子: 3.3
作者:
Jin, Ping;Madieh, Shadi;Augsburger, Larry L.
通讯作者: Augsburger, Larry L.
DOI: 10.1182/blood-2004-10-4135
发表时间: 2005-06-01
期刊: BLOOD
影响因子: 20.3
作者:
Guzman, ML;Rossi, RM;Jordan, CT
通讯作者: Jordan, CT
DOI: 10.1016/j.cell.2014.07.048
发表时间: 2014-09-11
期刊: Cell
影响因子: 64.5
作者:
Wang YH;Israelsen WJ;Lee D;Yu VWC;Jeanson NT;Clish CB;Cantley LC;Vander Heiden MG;Scadden DT
通讯作者: Scadden DT